Associate Professor

Jordan Lerner-Ellis

Department of Laboratory Medicine & Pathobiology


Mount Sinai Hospital: Sinai Health
700 University Ave., Room 8-400-06-2, Toronto, Ontario Canada M5G 1Z5
Research Interests
Cancer, Genetics Genomics & Proteomics
Clinical Interests
Molecular Genetics
Appointment Status
Accepting MSc students, Accepting PhD students

Dr Lerner-Ellis is a molecular geneticist who serves as Head and Director of the Advanced Molecular Diagnostics Laboratory at Mount Sinai Hospital and an Associate at the Ontario Institute for Cancer Research.  

In addition to his core interests in molecular diagnostics, as applied to breast and colon cancer, a major aim of his research is to integrate genome sequencing into the general practice of medicine.     

Research Synopsis

The MSH Advanced Molecular Diagnostics Laboratory: unique resources and activities

The Advanced Molecular Diagnostics Laboratory (AMD) at Toronto’s Mount Sinai Hospital (MSH) is a clinically certified lab that serves as an international reference centre for molecular diagnostics.

Our lab has been carrying out diagnostic testing for over 15 years, with special concentration on hereditary breast, ovarian (BRCA1, BRCA2); and colon cancer (Lynch syndrome, APC- and MUTYH-associated polyposis).

Our clinical services extend to tumour genotyping and microsatellite instability (MSI); KRAS; gastrointestinal stromal tumours (PDGFRA, cKIT); a variety of sarcomas; and coagulopathies (F2, F5, MTHFR, HFE).

The AMD, located within Mount Sinai’s Department of Pathology and Laboratory Medicine, works in direct collaboration with a team of pathologists on the floor.

Our work is backed by a number of crucial in-house resources, including one of the world’s largest collections of cancer-related patient samples, which also comprises a large number of tumour-normal tissues and DNA specimens.

As a service genetics lab for clinicians, AMD processes approximately 10,000 patient samples per year.

In our testing we rely on a variety of technologies, including ABI capillary-based di-deoxy-sequencing.

Our key next-gen platform uses Illumina’s HiSeq and MiSeq sequencing instruments, which will allow us to support and extend the service and research commitments made by MSH.

Our diagnostic activities currently occupy 2,000 square feet, and we are making plans to expand the testing areas to allow coverage of adult-onset and familial genetic disorders. We are one of the first clinical centers in Canada to offer exome sequencing on a routine clinical basis.

In addition to our core service activities, we are committed to providing molecular training to clinical fellows and other members of staff. In our educational and research activities, we work in close collaboration with a team of medical geneticists and genetic counsellors, based within the hospital and across the community.

Major research activities

In my prior research, clinical training, and study I have focused on:

  • inborn errors of metabolism
  • type-2 diabetes
  • cardiomyopathies
  • connective tissue diseases
  • cancer.

My current research goals are geared towards providing major improvements in the clinical sensitivity of genetic testing through greater reliance on new sequencing technology. To this end, my colleagues and I are developing a framework for the analysis and identification of a wide range of disorders characterized by late onset and variable penetrance.

A concurrent aim of my research is the identification of new genes and genomic variants of clinical relevance.

In one study, we are sequencing the exomes of cancer patients with a view to identifying novel genes and developing improved therapies. In carrying out this work, I will be making a concerted effort to determine the extent to which exome sequencing can be used in the diagnosis, treatment and prevention of disease, and to address the many challenges related to integrating genome sequencing into the general practice of medicine.   

Selected Publications

Wang M, Aldubayan S, Connor AA, Wong B, Mcnamara K, Khan T, Semotiuk K, Khalouei S, Holter S, Aronson M, Cohen Z, Gallinger S, Charames G, Pollett A, Lerner-Ellis J. Genetic testing for Lynch syndrome in the province of Ontario. Cancer. 2016 Mar 28. doi: 10.1002/cncr.29950. [Epub ahead of print] PubMed PMID: 27019099.

Lerner-Ellis J, Khalouei S, Sopik V, Narod SA. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Expert Rev Anticancer Ther. 2015 Nov;15(11):1315-26. doi: 10.1586/14737140.2015.1090879.  Epub 2015 Nov 2. PubMed PMID: 26523341.

Finch A, Wang M, Fine A, Atri L, Khalouei S, Pupavac M, Rosen B, Eisen A, Elser C, Charames G, Metcalfe K, Chang MC, Narod SA, Lerner-Ellis J. Genetic testing for BRCA1 and BRCA2 in the Province of Ontario. Clin Genet. 2016 Mar;89(3):304-11. doi: 10.1111/cge.12647. Epub 2015 Aug 31. PubMed PMID: 26219728.

Lerner-Ellis J, Wang M, White S, Lebo MS; Canadian Open Genetics Repository Group. Canadian Open Genetics Repository (COGR): a unified clinical genomics database as a community resource for standardising and sharing genetic interpretations. J Med Genet. 2015 Jul;52(7):438-45. doi: 10.1136/jmedgenet-2014-102933. Epub 2015 Apr 22. PubMed PMID: 25904639; PubMed Central PMCID: PMC4501169.

Lerner-Ellis JP. The clinical implementation of whole genome sequencing: a conversation with seven scientific experts. J Inherit Metab Dis. 2012 Jul;35(4):689-93. doi: 10.1007/s10545-012-9463-4. Epub 2012 Mar 9. PubMed PMID: 22403015.